The stock of Neurocrine Biosciences, Inc (NASDAQ: NBIX) has decreased by -0.07 when compared to last closing price of 117.59.Despite this, the company has seen a gain of 1.21% in its stock price over the last five trading days. prnewswire.com reported 2025-02-27 that SAN DIEGO, Feb. 27, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD), irrespective of TD severity or underlying psychiatric condition. KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale used to evaluate the physical, social and emotional impact of involuntary movements.
Is It Worth Investing in Neurocrine Biosciences, Inc (NASDAQ: NBIX) Right Now?
The price-to-earnings ratio for Neurocrine Biosciences, Inc (NASDAQ: NBIX) is above average at 35.71x. The 36-month beta value for NBIX is also noteworthy at 0.35. There are mixed opinions on the stock, with 15 analysts rating it as a “buy,” 6 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for NBIX is 96.83M, and at present, short sellers hold a 3.14% of that float. The average trading volume of NBIX on February 28, 2025 was 1.18M shares.
NBIX’s Market Performance
NBIX’s stock has seen a 1.21% increase for the week, with a -22.03% drop in the past month and a -6.48% fall in the past quarter. The volatility ratio for the week is 2.65%, and the volatility levels for the past 30 days are at 3.14% for Neurocrine Biosciences, Inc The simple moving average for the past 20 days is -7.90% for NBIX’s stock, with a -11.20% simple moving average for the past 200 days.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Deutsche Bank repeating the rating for NBIX by listing it as a “Hold.” The predicted price for NBIX in the upcoming period, according to Deutsche Bank is $138 based on the research report published on February 11, 2025 of the current year 2025.
Raymond James, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $155. The rating they have provided for NBIX stocks is “Outperform” according to the report published on October 10th, 2024.
Piper Sandler gave a rating of “Overweight” to NBIX, setting the target price at $159 in the report published on August 29th of the previous year.
NBIX Trading at -13.06% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.62% of loss for the given period.
Volatility was left at 3.14%, however, over the last 30 days, the volatility rate increased by 2.65%, as shares sank -22.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.32% lower at present.
During the last 5 trading sessions, NBIX rose by +1.21%, which changed the moving average for the period of 200-days by -15.86% in comparison to the 20-day moving average, which settled at $127.59. In addition, Neurocrine Biosciences, Inc saw -13.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from Cooke Julie, who sale 1,551 shares at the price of $116.78 back on Feb 13 ’25. After this action, Cooke Julie now owns 19,544 shares of Neurocrine Biosciences, Inc, valued at $181,129 using the latest closing price.
GORMAN KEVIN CHARLES, the Director of Neurocrine Biosciences, Inc, sale 5,844 shares at $116.69 during a trade that took place back on Feb 13 ’25, which means that GORMAN KEVIN CHARLES is holding 521,618 shares at $681,914 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc stands at 0.14. The total capital return value is set at 0.18. Equity return is now at value 14.16, with 9.51 for asset returns.
Based on Neurocrine Biosciences, Inc (NBIX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at 1.31. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 526.36.
Currently, EBITDA for the company is 610.1 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 5.07. The receivables turnover for the company is 4.92for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.40.
Conclusion
In summary, Neurocrine Biosciences, Inc (NBIX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
